Lonza plans new filling line for commercial supply of ADCs

13 October 2023

Swiss contract development and manufacturing organization (CDMO) Lonza today announced the extension of a collaboration with a major, named, biopharmaceutical partner for the commercial-scale filling of antibody-drug conjugates (ADCs).

Lonza said it will construct a dedicated commercial-scale aseptic cGMP filling line at its Stein site. The new dedicated filling line will enable the aseptic filling of highly-potent ADCs and lyophilization under containment. The additional filling capabilities further strengthen Lonza's capacity and flexibility in supporting both clinical and commercial supply of bioconjugates. The filling line is expected to be operational in 2027 and is anticipated to create approximately 115 new jobs at peak capacity.

In June this year, Lonza acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of ADCs), thus expanding its presence in the sector.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK